NEW YORK (GenomeWeb News) – Epigenomics today said that revenues for full-year 2012 slipped 29 percent.

The German cancer molecular diagnostics company said revenues for the year ended Dec. 31, 2012 totaled €1.0 ($1.3 million), down from €1.4 million in 2011. Revenues resulted from product sales of the company's Epi proColon kits for colorectal cancer testing, royalty payments, and partnering fees.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.